Pasithea Therapeutics Corp.
Price Action
Technical Summary
WEAKENINGPasithea Therapeutics Corp. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 14), showing significant lag compared to the market leaders. Earnings growth of 87% provides fundamental context to the price action. Investors should exercise caution due to high volatility (100% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.58 | -6.74% | BELOW |
| 50 SMA | $0.68 | -20.16% | BELOW |
| 100 SMA | $0.73 | -25.69% | BELOW |
| 150 SMA | $0.82 | -33.54% | BELOW |
| 200 SMA | $0.80 | -32.04% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KTTA in an uptrend right now?
KTTA has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is KTTA overbought or oversold?
KTTA's RSI (14) is 35. The stock is in neutral territory, neither overbought nor oversold.
Is KTTA outperforming the market?
KTTA has a Relative Strength (RS) Rating of 14 out of 99. KTTA is currently lagging the broader market.
Where is KTTA in its 52-week range?
KTTA is trading at $0.54, which is 26% of its 52-week high ($2.06) and 15% above its 52-week low ($0.28).
How volatile is KTTA?
KTTA has a Beta of 1.02 and 52-week volatility of 100%. It's more volatile than the S&P 500 - expect bigger swings.